MaxCyte Diluted EPS
The Diluted Earnings per Share of MaxCyte (MXCT) as of Sep 27, 2026 is -0.42 USD. In the previous year, Diluted Earnings per Share was -0.39 USD — a change of 7.10% (lower).
Get this data via API
Financial Data API
Diluted EPS
-0.42USD
YoY
7.10%
Last updated:
Diluted Earnings per Share of MaxCyte is 2026 -0.42 USD. Diluted Earnings per Share of MaxCyte was 2025 -0.39 USD. It decreases by 7.10% lower compared to the previous year.
The MaxCyte Diluted EPS history
3 Years
10 Years
25 Years
Max
Diluted EPS
Date
Diluted EPS
Jan 1, 2018
-0.17 USD
Jan 1, 2019
-0.22 USD
Jan 1, 2020
-0.15 USD
Jan 1, 2021
-0.19 USD
Jan 1, 2022
-0.23 USD
Jan 1, 2023
-0.37 USD
Jan 1, 2024
-0.39 USD
Jan 1, 2025
-0.42 USD
| YEAR | Diluted EPS | YoY |
|---|---|---|
| -0.42USD | +7.10% | |
| -0.39USD | +7.08% | |
| -0.37USD | +58.43% | |
| -0.23USD | +21.96% | |
| -0.19USD | +23.46% | |
| -0.15USD | -31.74% | |
| -0.22USD | +29.87% | |
| -0.17USD | -11.27% | |
| -0.19USD | +154.11% | |
| -0.08USD | -89.94% | |
| -0.76USD | -82.31% | |
| -4.31USD | — |
Access this data via the Eulerpool API
MaxCyte Stock analysis
What does MaxCyte do? MaxCyte Inc is a US biotechnology company specializing in the development of platform-based technologies for the next generation of gene and cell therapies. They offer integrated platform technology for drug manufacturing, research, and development. Their proprietary platform technology, Flow ElectroporationTM, allows for efficient transduction of a variety of cells, making it a valuable tool for the production of CAR-T cell therapies. They also offer services for lentiviral production and customized gene therapy production. MaxCyte has secured $50 million in funding for expansion and has formed important partnerships in the industry. They are a leading player in the development of innovative technologies for gene and cell therapy products. MaxCyte is one of the most popular companies on Eulerpool.
Frequently Asked Questions about MaxCyte stock
Diluted Earnings per Share of MaxCyte is -0.42 USD in 2026.
Diluted Earnings per Share of MaxCyte changed from -0.39 USD to -0.42 USD, representing a 7.10% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Diluted Earnings per Share MaxCyte since 2006 – with annual values, charts, and detailed analysis.
Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.
Access this data via the Eulerpool API
Income Statement — MaxCyte
All Key Metrics — MaxCyte
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth